Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

NCT ID: NCT04268706

Last Updated: 2023-04-05

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 97 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-01
• Study Completion Date: 2037-03-31

Brief Summary

This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.

Detailed Description

The Pilot part of the study will evaluate the safety, tolerability, and preliminary antitumor efficacy of CD30.CAR-T. The Pivotal part of the study will evaluate antitumor efficacy and further evaluate safety and tolerability. All study eligibility requirements, assessments, procedures, and follow-up are the same for patients in both Pilot and Pivotal parts of the study.

Subjects who meet eligibility criteria will have their blood drawn by leukapheresis for manufacture the CD30.CAR-T cells. Subjects are allowed bridging chemotherapy, as per Investigator choice, while waiting for production of CD30.CAR-T. Lymphodepletion (LD) with fludarabine and bendamustine will be administered for 3 consecutive days starting on Day -5 to Day -3, prior to CD30.CAR-T infusion, which will be administered on Day 0 as a single IV infusion. Depending on disease status, eligible subjects may receive up to a total of two CD30.CAR-T infusions at the same dose, each with preceding LD chemotherapy.

Subjects will be closely monitored for safety and efficacy throughout the Treatment Period until the end of study (EOS) visit at Month 24. Subjects will be followed for survival, withdrawal of consent or study closure, whichever occurs first. Health Related Quality of Life assessments will also be collected throughout the study. After the EOS visit, subjects will enter the long-term follow-up phase (LTFU) which will include survival follow-up, additional safety, efficacy and biomarker assessments, as clinically indicated.

Conditions

Hodgkin Lymphoma, Adult; Hodgkin Disease Recurrent; Hodgkin Disease Refractory; Hodgkin Disease, Pediatric

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CD30 positive r/r classical Hodgkin Lymphoma

Patients with relapsed or refractory classical Hodgkin Lymphoma who have failed 3 prior lines of treatment, which may include a prior autologous and/or allogeneic stem cell transplant.

Patients will be treated with autologous CD30.CAR-T cells.

Group Type: EXPERIMENTAL

CD30.CAR-T

Intervention Type: DRUG

Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.

Fludarabine

Intervention Type: DRUG

Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days

Bendamustine

Intervention Type: DRUG

Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days

Interventions

CD30.CAR-T

Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.

Intervention Type: DRUG

Fludarabine

Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days

Intervention Type: DRUG

Bendamustine

Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days

Intervention Type: DRUG

Other Intervention Names

Fludara; Bendeka

Eligibility Criteria

Inclusion Criteria

Eligibility is determined prior to blood collection . Patients must satisfy the following criteria to be enrolled in the study:

1. Signed Informed Consent Form

2. Male or female patients who are 12 - 75 years of age

3. Histologically confirmed classical Hodgkin Lymphoma

4. Relapsed or refractory cHL that has failed at least 3 prior lines of therapy, including:

• chemotherapy
• BV and/or
• PD-1 inhibitor Patients may have previously received an autologous and/or allogeneic stem cell transplant

5. CD30-positive tumor

6. At least 1 measurable lesion according to The Lugano Classification

7. Laboratory parameters: Hematological, renal and hepatic functions, and coagulation parameters

• Hgb ≥ 8.0 g/dL
• Total bilirubin ≤ 1.5 × ULN
• AST and ALT ≤ 5 × the ULN
• CrCl > 45 mL/min
• ANC >1,000/µL
• Platelets >75,000/µL
• PT or INR ≤ 1.5 × ULN; PTT or aPTT ≤ 1.5 × ULN

8. ECOG PS of 0 to 1 or equivalent [either Karnofsky PS (for patients ≥ 16 year of age) or Lansky PS (for patients < 16 years of age)]

9. Anticipated life expectancy > 12 weeks

Exclusion Criteria

1. Evidence of lymphomatous involvement of central nervous system (CNS)

2. Presence of clinically relevant or active seizure disorder, stroke, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement

3. Active uncontrolled bleeding or a known bleeding diathesis

4. Inadequate pulmonary function defined as pulse oximetry < 90% on room air

5. ECHO or MUGA with LVEF < 45%

6. On-going treatment with immunosuppressive drugs or chronic systemic corticosteroids

7. Having received:

• Anti-CD30 antibody-based therapy within 4 weeks prior to CD30.CAR-T infusion
• Prior investigational CD30.CAR-T
• CD30 bispecific agent within 8 weeks prior to CD30.CAR-T infusion
• Autologous HSCT within 90 days or allogeneic HSCT within 180 days prior to CD30.CAR-T infusion

8. Currently receiving any investigational agents within 4 weeks prior to study enrollment; or received any tumor vaccines within 6 weeks prior to CD30.CAR-T infusion

9. Active acute or chronic graft versus host disease (GVHD) requiring immune suppression regardless of grade

10. Evidence of human immunodeficiency virus (HIV) infection

11. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)

12. Unresolved > Grade 1 non-hematologic toxicity associated with any prior treatments

13. History of hypersensitivity reactions to murine protein-containing products or other product excipients

14. Symptomatic cardiovascular disease: Class III or IV according to the New York Heart Association (NYHA) Functional Classification

15. Active second malignancy or history of another malignancy within the last 3 years

16. Women who are pregnant or intending to become pregnant; women who are breastfeeding; persons with procreative potential not using and not willing to use 2 highly effective methods of contraception

17. Any other serious, life-threatening, or unstable preexisting medical conditions

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tessa Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Helen Heslop, MD

Role: PRINCIPAL_INVESTIGATOR

Baylor College of Medicine

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

MD Anderson Cancer Center

Houston, Texas, United States

Countries

United States

Other Identifiers

TESSCAR001

Identifier Type: -

Identifier Source: org_study_id